REMARKS/ARGUMENTS

The specification has been amended to include a cross-reference to the parent applications and to include the published Abstract.

The claims have been amended based on the published claims. Claims 2-177 have been canceled, without prejudice.

The requisite filing fee is attached.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____
B. J. Sadoff
Reg. No. 36,663

BJS:ecb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

ABSTRACT

This invention pertains to certain acridone and acridine compounds of the formula which inhibit telomerase, regulate cell proliferation, etc., and/or treat cancer, proliferative conditions, etc.: wherein either: (a) K is =O, L is -H, alpha single bond, beta is a double bond, gamma is a single bond (acridones); or, (b) K is a 9-substituent, L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond (acridines); and wherein: J^1 is a 2- or 3-substituent; J^2 is a 6- or 7-substituent; J^1 and J^2 are each a group of the formula $-N(R^N)-W$, wherein: R^N is a nitrogen substituent and is hydrogen, C_{1-7}alkyl, C_{3-20}heterocyclyl, or C_{5-20}aryl, and is optionally substituted; and, W is C_{1-7}alkyl, C_{3-20}heterocyclyl, or C_{5-20}aryl, and is optionally substituted; and, wherein, when K is a 9-substituent, K is a group of the formula $-N(R^N)-Q$, wherein: R^N is an amino substituent and is hydrogen, C_{1-7}alkyl, C_{3-20}heterocyclyl, or C_{5-20}aryl; and, Q is C_{1-7}alkyl, C_{3-20}heterocyclyl, or C_{5-20}aryl, and is optionally substituted; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both *in vitro* and *in vivo*, to inhibit telomerase, to regulate cell proliferation, etc., and/or in the treatment of cancer, proliferative conditions, etc.